Ligence develops AI-powered software that automatically analyses echocardiography images, helping cardiologists make quicker and more precise clinical decisions while reducing manual workload. The platform integrates with hospital PACS and IT systems and follows ASE and ESC guidelines, allowing seamless adoption in clinical settings. Its product is already deployed in Lithuania and several other European countries, including Poland, Switzerland, Germany, France, Spain, Portugal, and the United Kingdom, and is being piloted in Morocco. Ongoing clinical trials in the United States, Germany, the Netherlands, Poland, and Lithuania aim to further validate the technology’s diagnostic accuracy and efficiency. By improving diagnostic speed and standardisation, Ligence seeks to enhance early detection of cardiovascular disease—the world’s leading cause of death—and free physicians to spend more time with patients. The company’s social-impact mission aligns with investors focused on measurable healthcare improvements. Ligence’s recently raised capital strengthens its financial footing to deepen R&D, scale commercial operations across Europe, and prepare for broader U.S. market entry.

Total raised

$4M

Funding rounds

2

Latest round

Seed

Latest activity

Nov 2024